Research on new treatments for multiple myeloma
Investigation of the Activity of Novel Compounds for the Treatment of Myeloma and Mechanisms of Drug Resistance to Current Therapies
This study is testing new treatments for multiple myeloma by collecting blood and bone marrow samples from patients to find better options with fewer side effects.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institute of Cancer Research, United Kingdom Academic / other |
| Locations | 1 site (Sutton) |
| Trial ID | NCT05968417 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on multiple myeloma, a type of bone marrow cancer affecting thousands of patients annually in the UK. Researchers aim to enhance the understanding of myeloma and develop more effective treatments with fewer side effects. To achieve this, they will collect blood and bone marrow samples from participants to test potential new treatments in the laboratory and investigate reasons why some treatments may not be effective. The study involves participants who are already undergoing routine sampling for diagnostic or treatment purposes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a diagnosis or suspected diagnosis of myeloma or related plasma cell disorders who are undergoing blood or bone marrow sampling.
Not a fit: Patients unable to provide consent or those with active infectious diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for multiple myeloma, enhancing patient outcomes and reducing side effects.
How similar studies have performed: Other studies focusing on similar approaches in understanding and treating multiple myeloma have shown promise, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder 2. Participants who are undergoing a peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment 3. Participants aged 18 years of age or above 4. Participants willing to consent to an additional sample being taken at the time of their peripheral blood or bone marrow aspirate sampling Exclusion Criteria: 1. Participants unable to provide consent 2. Participants with known active infectious diseases (e.g. HIV, Hepatitis B/C, COVID) that pose a risk to the use of the sample in the laboratory
Where this trial is running
Sutton
- The Royal Marsden NHS Foundation Trust — Sutton, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Disco Team
- Email: Disco.iras263630@nhs.net
- Phone: 020 3186 5275
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.